Contribution of intestinal smooth muscle to Crohn's disease fibrogenesis

C Severi1, R Sferra, A Scirocco

  • 1La Sapienza University of Rome. carola.severi@uniroma1.it.

Insights

Intrinsic myogenic alterations in Crohn's disease (CD) ileum precede stricture formation. Smooth muscle cells (SMCs) show altered gene expression and function, suggesting new anti-fibrotic therapeutic targets for CD fibrosis.

Area of Science:

  • Gastroenterology
  • Cell Biology
  • Fibrosis Research

Background:

  • Mesenchymal cells and extracellular matrix deposition drive fibrosis in Crohn's disease (CD).
  • Smooth muscle cell (SMC) de-differentiation, influenced by Platelet-derived growth factor (PDGF) and Transforming growth factor-beta (TGF-β), is implicated in vascular muscle but not fully understood in intestinal fibrogenesis.
  • The specific role of SMCs in the fibrotic processes of CD requires further elucidation.

Purpose of the Study:

  • To investigate the myogenic contribution to CD fibrotic processes.
  • To comparatively analyze histological, morphometric, and molecular changes in human intestinal smooth muscle from CD patients and controls.
  • To assess alterations in SMCs isolated from CD ileum.

Main Methods:

  • Histological and immunohistochemical (IHC) analysis of full-thickness ileum specimens (CD non-involved, CD stenotic, and control).
  • Isolation and characterization of SMCs from the muscularis propria.
  • Morphofunctional assessment and quantitative real-time PCR (qPCR) analysis of isolated SMCs.

Main Results:

  • CD stenotic ileum exhibited significant thickening of all layers compared to non-involved CD and control ileum.
  • IHC revealed overexpression of alpha-smooth muscle actin and collagens I-III in stenotic CD tracts.
  • SMCs from CD ileum showed progressive alterations, including increased PDGF-β and collagen III mRNA, decreased TGF-β and Tribbles-like protein-3 mRNA, reduced cell length, and diminished contractility.

Conclusions:

  • Intrinsic myogenic alterations occur in the ileum of CD patients and precede stricture formation.
  • Altered SMCs in CD ileum may play a significant role in intestinal fibrogenesis.
  • These findings highlight potential new therapeutic targets for anti-fibrotic interventions in CD.

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
2
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
3
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
821
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
958
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
4